APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Prophylactic HIV Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Prophylactic HIV Drug Industry Growth and Trends Forecast to 2032

Report ID 174029070122 December 202596 pages

Choose your research edition.

Industry ResearchProphylactic HIV Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Prophylactic HIV Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Prophylactic HIV Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prophylactic HIV Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Prophylactic HIV Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Prophylactic HIV Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Prophylactic HIV Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Prophylactic HIV Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Prophylactic HIV Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Prophylactic HIV Drug include Merck, Mylan, Roche, Gilead Sciences, Cipla and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Prophylactic HIV Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Prophylactic HIV Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Prophylactic HIV Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Prophylactic HIV Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Prophylactic HIV Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Prophylactic HIV Drug Market by Company

Merck

Mylan

Roche

Gilead Sciences

Cipla

Bristol-Myers Squibb

Prophylactic HIV Drug Segment by Type

Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)

Integrase Inhibitor

Prophylactic HIV Drug Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Prophylactic HIV Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prophylactic HIV Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prophylactic HIV Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prophylactic HIV Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Prophylactic HIV Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Prophylactic HIV Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Table 2. Major Company of Integrase Inhibitor Table 3. Global Prophylactic HIV Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Prophylactic HIV Drug Sales by Type (2021-2026) & (k units) Table 5. Global Prophylactic HIV Drug Sales Market Share in Volume by Type (2021-2026) Table 6. Global Prophylactic HIV Drug Sales by Type (2021-2026) & (US$ Million) Table 7. Global Prophylactic HIV Drug Sales Market Share in Value by Type (2021-2026) Table 8. Global Prophylactic HIV Drug Price by Type (2021-2026) & (US$/unit) Table 9. Global Prophylactic HIV Drug Sales by Type (2027-2032) & (k units) Table 10. Global Prophylactic HIV Drug Sales Market Share in Volume by Type (2027-2032) Table 11. Global Prophylactic HIV Drug Sales by Type (2027-2032) & (US$ Million) Table 12. Global Prophylactic HIV Drug Sales Market Share in Value by Type (2027-2032) Table 13. Global Prophylactic HIV Drug Price by Type (2027-2032) & (US$/unit) Table 14. North America Prophylactic HIV Drug Sales by Type (2021-2026) & (k units) Table 15. North America Prophylactic HIV Drug Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Prophylactic HIV Drug Sales by Type (2021-2026) & (k units) Table 17. Europe Prophylactic HIV Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Prophylactic HIV Drug Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Prophylactic HIV Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Prophylactic HIV Drug Sales by Type (2021-2026) & (k units) Table 21. Latin America Prophylactic HIV Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Prophylactic HIV Drug Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Prophylactic HIV Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Prophylactic HIV Drug Industry Trends Table 25. Prophylactic HIV Drug Industry Drivers Table 26. Prophylactic HIV Drug Industry Opportunities and Challenges Table 27. Prophylactic HIV Drug Industry Restraints Table 28. Global Prophylactic HIV Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Prophylactic HIV Drug Revenue Market Share by Company (2021-2026) Table 30. Global Prophylactic HIV Drug Sales by Company (2021-2026) & (k units) Table 31. Global Prophylactic HIV Drug Sales Share by Company (2021-2026) Table 32. Global Prophylactic HIV Drug Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Prophylactic HIV Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Prophylactic HIV Drug Major Company Production Sites and Headquarters Table 35. Global Prophylactic HIV Drug Company, Product Type & Application Table 36. Global Prophylactic HIV Drug Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Prophylactic HIV Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Prophylactic HIV Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Prophylactic HIV Drug Sales by Region (2021-2026) & (k units) Table 41. Global Prophylactic HIV Drug Sales Market Share in Volume by Region (2021-2026) Table 42. Global Prophylactic HIV Drug Sales by Region (2021-2026) & (US$ Million) Table 43. Global Prophylactic HIV Drug Sales Market Share in Value by Region (2021-2026) Table 44. Global Prophylactic HIV Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Prophylactic HIV Drug Sales by Region (2027-2032) & (k units) Table 46. Global Prophylactic HIV Drug Sales Market Share in Volume by Region (2027-2032) Table 47. Global Prophylactic HIV Drug Sales by Region (2027-2032) & (US$ Million) Table 48. Global Prophylactic HIV Drug Sales Market Share in Value by Region (2027-2032) Table 49. Global Prophylactic HIV Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Prophylactic HIV Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Prophylactic HIV Drug Sales by Application (2021-2026) & (k units) Table 52. Global Prophylactic HIV Drug Sales Market Share in Volume by Application (2021-2026) Table 53. Global Prophylactic HIV Drug Sales by Application (2021-2026) & (US$ Million) Table 54. Global Prophylactic HIV Drug Sales Market Share in Value by Application (2021-2026) Table 55. Global Prophylactic HIV Drug Price by Application (2021-2026) & (US$/unit) Table 56. Global Prophylactic HIV Drug Sales by Application (2027-2032) & (k units) Table 57. Global Prophylactic HIV Drug Sales Market Share in Volume by Application (2027-2032) Table 58. Global Prophylactic HIV Drug Sales by Application (2027-2032) & (US$ Million) Table 59. Global Prophylactic HIV Drug Sales Market Share in Value by Application (2027-2032) Table 60. Global Prophylactic HIV Drug Price by Application (2027-2032) & (US$/unit) Table 61. North America Prophylactic HIV Drug Sales by Application (2021-2026) & (k units) Table 62. North America Prophylactic HIV Drug Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Prophylactic HIV Drug Sales by Application (2021-2026) & (k units) Table 64. Europe Prophylactic HIV Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Prophylactic HIV Drug Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Prophylactic HIV Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Prophylactic HIV Drug Sales by Application (2021-2026) & (k units) Table 68. Latin America Prophylactic HIV Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Prophylactic HIV Drug Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Prophylactic HIV Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Merck Prophylactic HIV Drug Product Portfolio Table 75. Merck Recent Development Table 76. Mylan Company Information Table 77. Mylan Business Overview Table 78. Mylan Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Mylan Prophylactic HIV Drug Product Portfolio Table 80. Mylan Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Roche Prophylactic HIV Drug Product Portfolio Table 85. Roche Recent Development Table 86. Gilead Sciences Company Information Table 87. Gilead Sciences Business Overview Table 88. Gilead Sciences Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Gilead Sciences Prophylactic HIV Drug Product Portfolio Table 90. Gilead Sciences Recent Development Table 91. Cipla Company Information Table 92. Cipla Business Overview Table 93. Cipla Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Cipla Prophylactic HIV Drug Product Portfolio Table 95. Cipla Recent Development Table 96. Bristol-Myers Squibb Company Information Table 97. Bristol-Myers Squibb Business Overview Table 98. Bristol-Myers Squibb Prophylactic HIV Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Bristol-Myers Squibb Prophylactic HIV Drug Product Portfolio Table 100. Bristol-Myers Squibb Recent Development Table 101. North America Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 102. North America Prophylactic HIV Drug Sales by Country (2021-2026) & (k units) Table 103. North America Prophylactic HIV Drug Sales Market Share by Country (2021-2026) Table 104. North America Prophylactic HIV Drug Sales Forecast by Country (2027-2032) & (k units) Table 105. North America Prophylactic HIV Drug Sales Market Share Forecast by Country (2027-2032) Table 106. North America Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 107. North America Prophylactic HIV Drug Market Size by Country (2021-2026) & (US$ Million) Table 108. North America Prophylactic HIV Drug Market Share by Country (2021-2026) Table 109. North America Prophylactic HIV Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 110. North America Prophylactic HIV Drug Market Share Forecast by Country (2027-2032) Table 111. Europe Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 112. Europe Prophylactic HIV Drug Sales by Country (2021-2026) & (k units) Table 113. Europe Prophylactic HIV Drug Sales Market Share by Country (2021-2026) Table 114. Europe Prophylactic HIV Drug Sales Forecast by Country (2027-2032) & (k units) Table 115. Europe Prophylactic HIV Drug Sales Market Share Forecast by Country (2027-2032) Table 116. Europe Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. Europe Prophylactic HIV Drug Market Size by Country (2021-2026) & (US$ Million) Table 118. Europe Prophylactic HIV Drug Market Share by Country (2021-2026) Table 119. Europe Prophylactic HIV Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. Europe Prophylactic HIV Drug Market Share Forecast by Country (2027-2032) Table 121. Asia-Pacific Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 122. Asia-Pacific Prophylactic HIV Drug Sales by Country (2021-2026) & (k units) Table 123. Asia-Pacific Prophylactic HIV Drug Sales Market Share by Country (2021-2026) Table 124. Asia-Pacific Prophylactic HIV Drug Sales Forecast by Country (2027-2032) & (k units) Table 125. Asia-Pacific Prophylactic HIV Drug Sales Market Share Forecast by Country (2027-2032) Table 126. Asia-Pacific Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Asia-Pacific Prophylactic HIV Drug Market Size by Country (2021-2026) & (US$ Million) Table 128. Asia-Pacific Prophylactic HIV Drug Market Share by Country (2021-2026) Table 129. Asia-Pacific Prophylactic HIV Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Asia-Pacific Prophylactic HIV Drug Market Share Forecast by Country (2027-2032) Table 131. Latin America Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 132. Latin America Prophylactic HIV Drug Sales by Country (2021-2026) & (k units) Table 133. Latin America Prophylactic HIV Drug Sales Market Share by Country (2021-2026) Table 134. Latin America Prophylactic HIV Drug Sales Forecast by Country (2027-2032) & (k units) Table 135. Latin America Prophylactic HIV Drug Sales Market Share Forecast by Country (2027-2032) Table 136. Latin America Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Latin America Prophylactic HIV Drug Market Size by Country (2021-2026) & (US$ Million) Table 138. Latin America Prophylactic HIV Drug Market Share by Country (2021-2026) Table 139. Latin America Prophylactic HIV Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Latin America Prophylactic HIV Drug Market Share Forecast by Country (2027-2032) Table 141. Middle East and Africa Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 142. Middle East and Africa Prophylactic HIV Drug Sales by Country (2021-2026) & (k units) Table 143. Middle East and Africa Prophylactic HIV Drug Sales Market Share by Country (2021-2026) Table 144. Middle East and Africa Prophylactic HIV Drug Sales Forecast by Country (2027-2032) & (k units) Table 145. Middle East and Africa Prophylactic HIV Drug Sales Market Share Forecast by Country (2027-2032) Table 146. Middle East and Africa Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Middle East and Africa Prophylactic HIV Drug Market Size by Country (2021-2026) & (US$ Million) Table 148. Middle East and Africa Prophylactic HIV Drug Market Share by Country (2021-2026) Table 149. Middle East and Africa Prophylactic HIV Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Middle East and Africa Prophylactic HIV Drug Market Share Forecast by Country (2027-2032) Table 151. Key Raw Materials Table 152. Raw Materials Key Suppliers Table 153. Prophylactic HIV Drug Distributors List Table 154. Prophylactic HIV Drug Customers List Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Prophylactic HIV Drug Image Figure 2. Global Prophylactic HIV Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prophylactic HIV Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Prophylactic HIV Drug Sales (2021-2032) & (k units) Figure 5. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Image Figure 6. Global Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Sales YoY Growth (2021-2032) & (k units) Figure 7. Integrase Inhibitor Image Figure 8. Global Integrase Inhibitor Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Prophylactic HIV Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Prophylactic HIV Drug Market Share by Type 2025 VS 2032 Figure 11. North America Prophylactic HIV Drug Sales Market Share in Volume by Type in 2025 Figure 12. North America Prophylactic HIV Drug Sales Market Share in Value by Type in 2025 Figure 13. Europe Prophylactic HIV Drug Sales Market Share in Volume by Type in 2025 Figure 14. Europe Prophylactic HIV Drug Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Prophylactic HIV Drug Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Prophylactic HIV Drug Sales Market Share in Value by Type in 2025 Figure 17. Latin America Prophylactic HIV Drug Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Prophylactic HIV Drug Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Prophylactic HIV Drug Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Prophylactic HIV Drug Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Prophylactic HIV Drug Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Retail Pharmacy Image Figure 24. Global Retail Pharmacy Sales YoY Growth (2021-2032) & (k units) Figure 25. Online Pharmacy Image Figure 26. Global Online Pharmacy Sales YoY Growth (2021-2032) & (k units) Figure 27. Hospital Pharmacy Image Figure 28. Global Hospital Pharmacy Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Prophylactic HIV Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Prophylactic HIV Drug Market Share by Application 2025 VS 2032 Figure 31. North America Prophylactic HIV Drug Sales Market Share in Volume by Application in 2025 Figure 32. North America Prophylactic HIV Drug Sales Market Share in Value by Application in 2025 Figure 33. Europe Prophylactic HIV Drug Sales Market Share in Volume by Application in 2025 Figure 34. Europe Prophylactic HIV Drug Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Prophylactic HIV Drug Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Prophylactic HIV Drug Sales Market Share in Value by Application in 2025 Figure 37. Latin America Prophylactic HIV Drug Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Prophylactic HIV Drug Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Prophylactic HIV Drug Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Prophylactic HIV Drug Sales Market Share in Value by Application in 2025 Figure 41. North America Prophylactic HIV Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Prophylactic HIV Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Prophylactic HIV Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Prophylactic HIV Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Prophylactic HIV Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Prophylactic HIV Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Prophylactic HIV Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Prophylactic HIV Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Prophylactic HIV Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Prophylactic HIV Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Prophylactic HIV Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Prophylactic HIV Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Prophylactic HIV Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Prophylactic HIV Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Prophylactic HIV Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Prophylactic HIV Drug Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Prophylactic HIV Drug Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
  • Integrase Inhibitor
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Merck
  • Mylan
  • Roche
  • Gilead Sciences
  • Cipla
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Prophylactic HIV Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Prophylactic HIV Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Prophylactic HIV Drug Market by Type
  6. 1.3.1 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
  7. 1.3.2 Integrase Inhibitor
  8. 1.4 Global Prophylactic HIV Drug Market Size by Type
  9. 1.4.1 Global Prophylactic HIV Drug Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Prophylactic HIV Drug Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Prophylactic HIV Drug Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Prophylactic HIV Drug Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Prophylactic HIV Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Prophylactic HIV Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Prophylactic HIV Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Prophylactic HIV Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Prophylactic HIV Drug Industry Trends
  2. 2.2 Prophylactic HIV Drug Industry Drivers
  3. 2.3 Prophylactic HIV Drug Industry Opportunities and Challenges
  4. 2.4 Prophylactic HIV Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Prophylactic HIV Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Prophylactic HIV Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Prophylactic HIV Drug Price (2021-2026)
  4. 3.4 Global Prophylactic HIV Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Prophylactic HIV Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Prophylactic HIV Drug Company, Product Type & Application
  7. 3.7 Global Prophylactic HIV Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Prophylactic HIV Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Prophylactic HIV Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Prophylactic HIV Drug Tier 1, Tier 2, and Tier 3
4 Prophylactic HIV Drug Regional Status and Outlook
  1. 4.1 Global Prophylactic HIV Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Prophylactic HIV Drug Historic Market Size by Region
  3. 4.2.1 Global Prophylactic HIV Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Prophylactic HIV Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Prophylactic HIV Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Prophylactic HIV Drug Forecasted Market Size by Region
  7. 4.3.1 Global Prophylactic HIV Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Prophylactic HIV Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Prophylactic HIV Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Prophylactic HIV Drug by Application
  1. 5.1 Prophylactic HIV Drug Market by Application
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Hospital Pharmacy
  5. 5.2 Global Prophylactic HIV Drug Market Size by Application
  6. 5.2.1 Global Prophylactic HIV Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Prophylactic HIV Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Prophylactic HIV Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Prophylactic HIV Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Prophylactic HIV Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Prophylactic HIV Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Prophylactic HIV Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Prophylactic HIV Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Merck
  2. 6.1.1 Merck Company Information
  3. 6.1.2 Merck Business Overview
  4. 6.1.3 Merck Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Merck Prophylactic HIV Drug Product Portfolio
  6. 6.1.5 Merck Recent Developments
  7. 6.2 Mylan
  8. 6.2.1 Mylan Company Information
  9. 6.2.2 Mylan Business Overview
  10. 6.2.3 Mylan Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Mylan Prophylactic HIV Drug Product Portfolio
  12. 6.2.5 Mylan Recent Developments
  13. 6.3 Roche
  14. 6.3.1 Roche Company Information
  15. 6.3.2 Roche Business Overview
  16. 6.3.3 Roche Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Roche Prophylactic HIV Drug Product Portfolio
  18. 6.3.5 Roche Recent Developments
  19. 6.4 Gilead Sciences
  20. 6.4.1 Gilead Sciences Company Information
  21. 6.4.2 Gilead Sciences Business Overview
  22. 6.4.3 Gilead Sciences Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Gilead Sciences Prophylactic HIV Drug Product Portfolio
  24. 6.4.5 Gilead Sciences Recent Developments
  25. 6.5 Cipla
  26. 6.5.1 Cipla Company Information
  27. 6.5.2 Cipla Business Overview
  28. 6.5.3 Cipla Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Cipla Prophylactic HIV Drug Product Portfolio
  30. 6.5.5 Cipla Recent Developments
  31. 6.6 Bristol-Myers Squibb
  32. 6.6.1 Bristol-Myers Squibb Company Information
  33. 6.6.2 Bristol-Myers Squibb Business Overview
  34. 6.6.3 Bristol-Myers Squibb Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Bristol-Myers Squibb Prophylactic HIV Drug Product Portfolio
  36. 6.6.5 Bristol-Myers Squibb Recent Developments
7 North America by Country
  1. 7.1 North America Prophylactic HIV Drug Sales by Country
  2. 7.1.1 North America Prophylactic HIV Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Prophylactic HIV Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Prophylactic HIV Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Prophylactic HIV Drug Market Size by Country
  6. 7.2.1 North America Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Prophylactic HIV Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Prophylactic HIV Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Prophylactic HIV Drug Sales by Country
  2. 8.1.1 Europe Prophylactic HIV Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Prophylactic HIV Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Prophylactic HIV Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Prophylactic HIV Drug Market Size by Country
  6. 8.2.1 Europe Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Prophylactic HIV Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Prophylactic HIV Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Prophylactic HIV Drug Sales by Country
  2. 9.1.1 Asia-Pacific Prophylactic HIV Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Prophylactic HIV Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Prophylactic HIV Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Prophylactic HIV Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Prophylactic HIV Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Prophylactic HIV Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Prophylactic HIV Drug Sales by Country
  2. 10.1.1 South America Prophylactic HIV Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Prophylactic HIV Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Prophylactic HIV Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Prophylactic HIV Drug Market Size by Country
  6. 10.2.1 South America Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Prophylactic HIV Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Prophylactic HIV Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Prophylactic HIV Drug Sales by Country
  2. 11.1.1 Middle East and Africa Prophylactic HIV Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Prophylactic HIV Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Prophylactic HIV Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Prophylactic HIV Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Prophylactic HIV Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Prophylactic HIV Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Prophylactic HIV Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Prophylactic HIV Drug Value Chain Analysis
  2. 12.1.1 Prophylactic HIV Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Prophylactic HIV Drug Production Mode & Process
  7. 12.2 Prophylactic HIV Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Prophylactic HIV Drug Distributors
  10. 12.2.3 Prophylactic HIV Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst